-DOCSTART- -X- O
The -X- _ O
genus -X- _ O
Coronavirus -X- _ B-Patient
contains -X- _ O
about -X- _ O
25 -X- _ O
species -X- _ O
of -X- _ O
coronaviruses -X- _ B-Patient
( -X- _ I-Patient
CoVs -X- _ I-Patient
) -X- _ I-Patient
, -X- _ O
which -X- _ O
are -X- _ O
important -X- _ O
pathogens -X- _ O
causing -X- _ O
highly -X- _ O
prevalent -X- _ O
diseases -X- _ O
and -X- _ O
often -X- _ O
severe -X- _ O
or -X- _ O
fatal -X- _ O
in -X- _ O
humans -X- _ O
and -X- _ O
animals. -X- _ O
No -X- _ O
licensed -X- _ O
specific -X- _ O
drugs -X- _ O
are -X- _ O
available -X- _ O
to -X- _ O
prevent -X- _ O
their -X- _ O
infection. -X- _ O
Different -X- _ O
host -X- _ O
receptors -X- _ O
for -X- _ O
cellular -X- _ O
entry -X- _ O
, -X- _ O
poorly -X- _ O
conserved -X- _ O
structural -X- _ O
proteins -X- _ O
( -X- _ O
antigens -X- _ O
) -X- _ O
, -X- _ O
and -X- _ O
the -X- _ O
high -X- _ O
mutation -X- _ O
and -X- _ O
recombination -X- _ O
rates -X- _ O
of -X- _ O
CoVs -X- _ B-Patient
pose -X- _ O
a -X- _ O
significant -X- _ O
problem -X- _ O
in -X- _ O
the -X- _ O
development -X- _ O
of -X- _ O
wide-spectrum -X- _ O
anti-CoV -X- _ O
drugs -X- _ O
and -X- _ O
vaccines. -X- _ O
CoV -X- _ B-Patient
main -X- _ I-Patient
proteases -X- _ I-Patient
( -X- _ I-Patient
M -X- _ I-Patient
( -X- _ I-Patient
pro -X- _ I-Patient
) -X- _ I-Patient
s -X- _ I-Patient
) -X- _ I-Patient
, -X- _ O
which -X- _ O
are -X- _ O
key -X- _ O
enzymes -X- _ O
in -X- _ O
viral -X- _ O
gene -X- _ O
expression -X- _ O
and -X- _ O
replication -X- _ O
, -X- _ O
were -X- _ O
revealed -X- _ O
to -X- _ O
share -X- _ O
a -X- _ O
highly -X- _ O
conservative -X- _ O
substrate-recognition -X- _ O
pocket -X- _ O
by -X- _ O
comparison -X- _ O
of -X- _ O
four -X- _ O
crystal -X- _ O
structures -X- _ O
and -X- _ O
a -X- _ O
homology -X- _ O
model -X- _ O
representing -X- _ O
all -X- _ O
three -X- _ O
genetic -X- _ O
clusters -X- _ O
of -X- _ O
the -X- _ O
genus -X- _ O
Coronavirus. -X- _ B-Patient
This -X- _ O
conclusion -X- _ O
was -X- _ O
further -X- _ O
supported -X- _ O
by -X- _ O
enzyme -X- _ O
activity -X- _ O
assays. -X- _ O
Mechanism-based -X- _ B-Intervention
irreversible -X- _ I-Intervention
inhibitors -X- _ I-Intervention
were -X- _ O
designed -X- _ O
, -X- _ O
based -X- _ O
on -X- _ O
this -X- _ O
conserved -X- _ O
structural -X- _ O
region -X- _ O
, -X- _ O
and -X- _ O
a -X- _ O
uniform -X- _ O
inhibition -X- _ O
mechanism -X- _ O
was -X- _ O
elucidated -X- _ O
from -X- _ O
the -X- _ O
structures -X- _ O
of -X- _ O
M -X- _ O
( -X- _ O
pro -X- _ O
) -X- _ O
-inhibitor -X- _ O
complexes -X- _ O
from -X- _ O
severe -X- _ B-Patient
acute -X- _ I-Patient
respiratory -X- _ I-Patient
syndrome-CoV -X- _ I-Patient
and -X- _ O
porcine -X- _ O
transmissible -X- _ O
gastroenteritis -X- _ O
virus. -X- _ O
A -X- _ O
structure-assisted -X- _ O
optimization -X- _ O
program -X- _ O
has -X- _ O
yielded -X- _ O
compounds -X- _ O
with -X- _ O
fast -X- _ B-Outcome
in -X- _ I-Outcome
vitro -X- _ I-Outcome
inactivation -X- _ I-Outcome
of -X- _ I-Outcome
multiple -X- _ I-Outcome
CoV -X- _ I-Outcome
M -X- _ I-Outcome
( -X- _ I-Outcome
pro -X- _ I-Outcome
) -X- _ I-Outcome
s -X- _ I-Outcome
, -X- _ I-Outcome
potent -X- _ I-Outcome
antiviral -X- _ I-Outcome
activity -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
extremely -X- _ I-Outcome
low -X- _ I-Outcome
cellular -X- _ I-Outcome
toxicity -X- _ I-Outcome
in -X- _ I-Outcome
cell-based -X- _ I-Outcome
assays. -X- _ I-Outcome
Further -X- _ O
modification -X- _ O
could -X- _ O
rapidly -X- _ O
lead -X- _ O
to -X- _ O
the -X- _ O
discovery -X- _ O
of -X- _ O
a -X- _ O
single -X- _ O
agent -X- _ O
with -X- _ O
clinical -X- _ O
potential -X- _ O
against -X- _ O
existing -X- _ O
and -X- _ O
possible -X- _ O
future -X- _ O
emerging -X- _ O
CoV-related -X- _ B-Patient
diseases -X- _ I-Patient
. -X- _ O

